- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00404313
The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
October 19, 2015 updated by: Merck Sharp & Dohme LLC
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma
A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.
Study Overview
Study Type
Interventional
Enrollment (Actual)
688
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production
- Males and females 18-70 years of age
Exclusion Criteria:
- History of kidney or chronic liver disease
- Recent history of heart problems within the past 3 months
- Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 4
placebo
|
Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
|
Experimental: 1
MK0633 10 mg
|
Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks.
There will be 2 week period during which all patients will receive placebo to MK0633
|
Experimental: 2
MK0633 50 mg
|
Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks.
There will be 2 week period during which all patients will receive placebo to MK0633
|
Experimental: 3
MK0633 100 mg
|
Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks.
There will be 2 week period during which all patients will receive placebo to MK0633
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pulmonary function test data measured over 6 weeks
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall daytime and nighttime symptoms score, beta-agonist use, asthma exacerbations, asthma-specific quality of life questionnaire score, measured over 6 weeks
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
June 1, 2009
Study Registration Dates
First Submitted
November 21, 2006
First Submitted That Met QC Criteria
November 27, 2006
First Posted (Estimate)
November 28, 2006
Study Record Updates
Last Update Posted (Estimate)
October 20, 2015
Last Update Submitted That Met QC Criteria
October 19, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0633-007
- MK0633-007
- 2006_553
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on MK0633
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted